The future of japan's health care market cannot be forecast with certainty. However, because change in Japan is rarely revolutionary, and tends to evolve in step-wise, incremental fashion, a reasonable forecast of the future may be objectively based on current trends. In turn, these trends suggest specific corporate strategic initiatives to establish competitive positions in Japan's pharmaceutical market.
In this article, trends are identified in three areas, ie overall market growth, R&D and marketing/distribution. Corporate responses are then recommended. it concludes with a brief look at "non issues," or those factors which are not strategically relevant.
Market Growth Trends Rapid growth of disposable income is driving the demand for quality health care. The Japanese media, politicians and commentators (including US trade representatives) constantly debate quality of life issues. the debate is not about equality or entitlement - that was achieved 30 years ago and is firmly entrenched in the health care system. The quality debate relates to information. patients want to know why they are sick and what is being done to make them better. Doctors need quality information on the risks and benefits of therapy they prescribe, insurers (payers) need information on the costs and benefits of alternative treatment regimens.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze